Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 1—January 2021
Research Letter

Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA

Amy K. FeehanComments to Author , Cruz Velasco, Daniel Fort, Jeffrey H. Burton, Eboni G. Price-Haywood, Peter T. Katzmarzyk, Julia Garcia-Diaz, and Leonardo Seoane
Author affiliations: Ochsner Clinic Foundation, New Orleans, Louisiana, USA (A.K. Feehan, C. Velasco, D. Fort, J.H. Burton, E.G. Price-Haywood, J. Garcia-Diaz, L. Seoane); The University of Queensland Faculty of Medicine, Ochsner Clinical School, New Orleans (A.K. Feehan, E.G. Price-Haywood, J. Garcia-Diaz, L. Seoane); Pennington Louisiana State University, Baton Rouge, Louisiana, USA (P.T. Katzmarzyk); Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana, USA (L. Seoane)

Main Article

Table

Prevalence of past and present severe acute respiratory syndrome coronavirus 2 infections by race and ethnicity across Baton Rouge, Louisiana, after phased reopening, July 2020*

Race or ethnicity Positive no./total no. (% of sample) Residents >18 y, no. (% of population)* Any infection, raw,† % (95% CI) Any infection, weighted,‡ % (95% CI) Weighted point prevalence,§ % (95% CI) Weighted seroprevalence,¶ % (95% CI)
Total 128/2138 (100) 551,185 (100) 6.0 (5.0–7.1) 6.6 (5.7–7.7) 3.0 (2.3–3.7) 3.6 (2.8–4.4)
White alone 54/1431 (66.9) 332,445 (60.3) 3.8 (2.9–4.9) 4.2 (3.2–5.2) 2.4 (1.6–3.2) 1.8 (1.1–2.5)
Black or African American alone 57/516 (24.1) 177,950 (32.3) 11.0 (8.5–14.1) 11.0 (8.5–14.1) 3.5 (1.9–5.1) 7.5 (5.2–9.8)
Asian alone 2/59 (3.4) 13,630 (2.5) 3.4 (0.4–11.7) 3.5 (0.0–8.2) 1.7 (0.0–9.1) 1.7 (0.0–9.1)
Other# 1/28 (1.3) 7,025 (1.3) 3.6 (0.1–18.4) 2.7 (0.0–8.7) 0.0 2.7 (0.0–8.7)
Hispanic or Latino, any race 14/104 (4.9) 20,125 (3.7) 13.5 (7.6–21.6) 11.8 (5.6–18.0) 10.1 (4.3–15.9) 1.6 (0.0–4.0)

*Census 2018 population estimates. By August 2, 2020, a total of 17,093 state-aggregated, confirmed cases had been reported in Ascension, East Baton Rouge, Livingston, and West Baton Rouge parishes (4). 
†Percentage of sample with a PCR-positive test, an IgG-positive test, or both.
‡Census-weighted percentage of PCR-positive test, IgG-positive test, or both calculated to match 2018 racial demographics by parish and combined.
§Census-weighted percentage of PCR-positive and IgG-negative tests calculated to match 2018 racial demographics by parish and combined.
¶Census-weighted percentage of IgG–positive tests calculated to match 2018 racial demographics by parish and combined.
#Other includes American Indian or Alaska Native, Pacific Islander, and multiracial persons.

Main Article

References
  1. Feehan  AK, Fort  D, Garcia-Diaz  J, Price-Haywood  EG, Velasco  C, Sapp  E, et al. Seroprevalence of SARS-CoV-2 and infection fatality ratio, Orleans and Jefferson parishes, Louisiana, USA, May 2020. Emerg Infect Dis. 2020;26:27669. DOIPubMed
  2. Pollán  M, Pérez-Gómez  B, Pastor-Barriuso  R, Oteo  J, Hernán  MA, Pérez-Olmeda  M, et al.; ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396:53544. DOIPubMed
  3. Havers  FP, Reed  C, Lim  T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 sites in the United States, March 23–May 12, 2020. JAMA Intern Med. 2020 Jul 21 [Epub ahead of print].
  4. Louisiana Department of Public Health. Louisiana coronavirus COVID-19 information [cited 2020 Sep 20]. http://ldh.la.gov/Coronavirus
  5. Feehan  A, Fort  D, Garcia-Diaz  J, Price-Haywood  E, Velasco  C, Sapp  E, et al. Frequency of symptoms and asymptomatic SARS-CoV-2 infection in New Orleans, Louisiana after 7 weeks of a stay-at-home order [cited 2020 Sep 8]. https://ssrn.com/abstract=3633166
  6. US Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody testing [cited 2020 Aug 10]. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html
  7. Bryan  A, Pepper  G, Wener  MH, Fink  SL, Morishima  C, Chaudhary  A, et al. Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. J Clin Microbiol. 2020;58:e0094120. DOIPubMed

Main Article

Page created: October 23, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external